ERYTECH Pharma S.A. logo
ERYTECH Pharma S.A. ERYP
$ 0.78 1.3%

Annual report 2022
added 11-23-2024

report update icon

ERYTECH Pharma S.A. Balance Sheet 2011-2024 | ERYP

Annual Balance Sheet ERYTECH Pharma S.A.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -28.5 M -70.4 M -133 M -183 M -34.8 M -45.1 M -36.2 M -14.1 M 3.07 M -

Long Term Debt

- - 14.4 M 1.32 M 1.24 M 1.98 M 2.66 M 63 K 436 K 731 K 6.4 M -

Long Term Debt Current

775 K 1.82 M 1.61 M 1.42 M - - - - - - - -

Total Non Current Liabilities

- - 24.5 M 13.1 M 1.59 M 2.24 M 2.98 M 251 K 525 K 848 K 6.69 M -

Total Current Liabilities

- - - - - - - - - - - -

Total Liabilities

- - 53.9 M 33 M 22.2 M 13.8 M 9.33 M 5.87 M 4.78 M 4.36 M 14.2 M -

Deferred Revenue

- - 148 K 61 K 16 K - - - 368 K 649 K 943 K -

Retained Earnings

- - -73.3 M -62.7 M -38.2 M -33.5 M -21.9 M -15 M -8.86 M -8.14 M -2.17 M -

Total Assets

45.8 M 66.8 M 80.4 M 119 M 168 M 195 M 45 M 53 M 40.6 M 17.9 M 10.1 M -

Cash and Cash Equivalents

38.8 M 33.7 M 44.4 M 73.2 M 134 M 186 M 37.6 M - - - - -

Book Value

- 66.8 M 26.5 M 85.6 M 146 M 181 M 35.6 M 47.1 M 35.8 M 13.6 M -4.03 M -

Total Shareholders Equity

- - 26.5 M 85.6 M 146 M 181 M 35.6 M 47.1 M - - - -

All numbers in EUR currency

Quarterly Balance Sheet ERYTECH Pharma S.A.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 8.16 M - 8.82 M - 9.2 M - 10.5 M - 11.3 M - 8.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 23.9 M - 24 M - 24.5 M - 15.4 M - 13.1 M - 9.87 M - 1.59 M - - - 2.24 M - - - 2.98 M - - - 251 K - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - - - - - -35 M - -62.7 M - -29.3 M - -38.2 M - - - -33.5 M - - - -21.9 M - - - -15 M - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 66.8 M - 83.8 M - 80.4 M - 89.1 M - 119 M - 146 M - 168 M - - - 195 M - - - 45 M - - - 53 M - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 33.7 M - 46.3 M - 44.4 M - 45.4 M - 73.2 M - 94.5 M - 134 M - - - 186 M - - - 37.6 M - - - 45.6 M - - - 37 M - - - - - - - - - - - - - - -

Book Value

- - - - 66.8 M - 83.8 M - 80.4 M - 89.1 M - 119 M - 146 M - 168 M - - - 195 M - - - 45 M - - - 53 M - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 22.8 M - 36.4 M - 26.5 M - 51.1 M - 85.6 M - 117 M - 146 M - 164 M - 181 M - - - 35.6 M - - - 47.1 M - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency